{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=4", "query": { "condition": "Pancreatic Carcinoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 2230, "total_pages": 223, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T05:59:30.185Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01431794", "title": "Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "LDE225-600mg", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "LDE225-400mg", "type": "DRUG" }, { "name": "LDE225-800mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2011-12-27", "completion_date": "2018-11-05", "has_results": true, "last_update_posted_date": "2020-01-22", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431794" }, { "nct_id": "NCT01374451", "title": "Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Islet Cell Tumor" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Pasireotide LAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2011-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-12-20", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 4, "location_summary": "Boston, Massachusetts • The Bronx, New York • Portland, Oregon + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "The Bronx", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01374451" }, { "nct_id": "NCT01746979", "title": "Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "TH-302", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo (5 percent dextrose - D5W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGenesis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 693, "start_date": "2012-12", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01746979" }, { "nct_id": "NCT02713529", "title": "Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Colorectal Cancer", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "AMG820 and pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AmMax Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2016-04-14", "completion_date": "2019-05-17", "has_results": true, "last_update_posted_date": "2023-01-20", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 8, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713529" }, { "nct_id": "NCT05625529", "title": "ExoLuminate Study for Early Detection of Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreas Cancer", "Exosomes", "Extracellular Vesicles", "Pancreatic Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "Biological Dynamics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2022-12-19", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05625529" }, { "nct_id": "NCT03699319", "title": "CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "CPI 613", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-flurouracil", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Bajor, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 49, "start_date": "2018-12-07", "completion_date": "2024-09-23", "has_results": false, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03699319" }, { "nct_id": "NCT00323583", "title": "Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarincoma of Pancreas", "Stage III Pancreatic Cancer", "Stage IVA Pancreatic Cancer", "Stage IVB Pancreatic Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "glutathione", "type": "DRUG" }, { "name": "calcium and magnesium", "type": "DRUG" }, { "name": "Chemotherapy", "type": "PROCEDURE" }, { "name": "Chemoprotection", "type": "PROCEDURE" }, { "name": "Complementary and alternative therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Seattle Cancer Treatment and Wellness Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 80, "start_date": "2006-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-05-08", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00323583" }, { "nct_id": "NCT01580241", "title": "Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2010-10", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01580241" }, { "nct_id": "NCT00998322", "title": "A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "REOLYSIN", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Oncolytics Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2009-10", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-04-10", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 2, "location_summary": "New York, New York • San Antonio, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00998322" }, { "nct_id": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Itraconazole (ITZ)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2023-11-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-10T05:59:30.185Z", "location_count": 20, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084481" } ] }